A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies
Phase of Trial: Phase I
Latest Information Update: 27 May 2018
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trigriluzole (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 30 Oct 2017 According to a Biohaven Pharmaceutical Holding Company media release, the first patient has begun treatment in the trial.
- 16 Oct 2017 Status changed from not yet recruiting to recruiting.
- 11 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Oct 2017.